Contact us to place a job advertisement on this page
We are recruiting for a Head of Meetings and Events to join our team. This is a great opportunity to run the prestigious Meetings and Events function for the British Pharmacological Society. The Events calendar is busy with many high profile conferences, networking events and scientific meetings, with up to 1,500 delegates.
You'll be managing the Events Manager directly and supporting the Meetings Committee to ensure the Society's reputation is protected and enhanced through the delivery of high quality events throughout the year. This also involves partnering with international organisations and consequently some international travel - this year for instance to Hong Kong to work in partnership with the Australian pharmacological society, and to Austria.
The deadline for applications is 16 March 2015.
The British Journal of Pharmacology (BJP) is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. It publishes high quality original research and authoritative reviews and is published fortnightly. The British Pharmacological Society is seeking to appoint a new Editor-in-Chief to succeed Professor Ian McGrath who will complete a full term at the end of 2015. The Editor-in-Chief will be responsible for continuing to improve the quality of BJP, and driving new initiatives for the journal. The Editor-in-Chief will deliver strategic direction to the journal, and contribute more broadly to BPS’s publication strategy. View job description.
Please direct any questions regarding the recruitment process to Ruth Meyer (020 7417 0110, email@example.com). The deadline for applications is Monday 11 May 2015 and interviews will be held in the second week of June.
The Neurogastroenterology Group is a collaboration of scientists and clinicians working together to advance basic scientific study, and translate this knowledge to enhance care for patients with disorders of gastrointestinal function.
Applications are invited for two roles:
QMUL5327: Research Assistant to work on a 3 year programme of research into on-going efforts to define and understand the causes and treatments of changes in lower bowel neuromuscular functions associated with neuropathy and/ or with advanced age.
QMUL5328: Research Assistant to work on a 3 year programme of research into the etiology and methods of treatment of disrupted gastric movements, focusing on the regulation of slow wave activity, interstitial cell and neuromuscular functions, primarily in human isolated stomach.
The positions are funded by Takeda Pharmaceuticals. The successful candidates will work with existing laboratory and clinical personnel and with Takeda research scientists, undertaking fundamental research which will ultimately lead to the identification of novel drug targets. The post holders will be based in the National Centre for Bowel Research and Surgical Innovation, part of the Blizard Institute, Barts and the London School of Medicine and Dentistry under the supervision of Professor Gareth Sanger. The positions would suit candidates with a PhD degree in a life science and extensive experience in pharmacology, immunohistochemistry, electrophysiology and/ or molecular biology.
Starting salary will be in the range £31,735-£33,476 per annum inclusive of London Allowance. Benefits include 30 days annual leave, defined benefit pension scheme and interest-free season ticket loan.
Candidates must be able to demonstrate their eligibility to work in the UK in accordance with the Immigration, Asylum and Nationality Act 2006. Where required this may include entry clearance or continued leave to remain under the Points Based Immigration Scheme.
Informal enquiries should be addressed to Professor Gareth Sanger at firstname.lastname@example.org or on 0207 882 6027. Details about the Institute can be found at www.blizard.qmul.ac.uk To apply and for full job details including a job description and person specification please visit http://www.jobs.qmul.ac.uk/ and search for the appropriate reference.
The closing date for all applications is 6 March 2015. Interviews are expected to take place shortly afterwards.
We are seeking to recruit a talented individual whose activities complement our work in cancer, neuroscience or cardiovascular research. Research that leads to commercial applications will be encouraged, assisted by colleagues in the Kosterlitz Centre for Therapeutics, and the Marine Biodiscovery Centre. You should have a significant research portfolio in pharmacology, to enhance and expand our established team. Within the Institute of Medical Sciences (IMS) where you will be based, we have internationally recognised strengths through research in cannabinoids, G protein coupled receptors, medicinal chemistry and molecular imaging (PET/CT and MRI).
You will have a PhD in Pharmacology with a proven ability to attract regular funding and publish papers in high quality journals. Experience of teaching at undergraduate and postgraduate level including research student supervision is required.
The IMS is located on the Foresterhill Health Campus, jointly owned by the NHS and the University and one of the largest health care, research and training sites in Europe, where over £150m has been invested in recent years in infrastructure for new buildings and equipment. This co-location provides an ideal environment for partnerships between medical science researchers and clinical academics and their NHS colleagues. In addition to state-of-the-art buildings, the Core Facilities provide a suite of advanced technologies including flow-cytometry, proteomics, genomics and state-of-the art microscopy. The University merged with the Rowett Institute of Nutrition and Health in 2008 and colleagues from the Rowett will relocate to a new build at Foresterhill in 2015, further improving opportunities for joint programmes. The University of Aberdeen was among the institutions identified by the British Pharmacological Society as a UK site of special pharmacological interest.
For an appointment made at Professor level a competitive salary is available for outstanding candidates. For an appointments made at a Reader level salary will be at the appropriate point on Grade 8 (£48,743 to £54,841 per annum), with placement according to qualifications and experience.
Those who wish to discuss the post informally or arrange a visit should contact Professor Colin McCaig, Head of School of Medical Sciences (Tel +44 (0) 1224 437394, Email email@example.com), Professor Matteo Zanda, Chair in Medical Technologies (Tel +44 (0)1224 437513, Email firstname.lastname@example.org or Professor Peter McCaffery, Chair in Neuroscience and Co-Director of the Institute of Medical Sciences (Tel +44 (0)1224 437362, Email email@example.com).
Should you require a visa to undertake paid employment in the UK you will be required to fulfil the minimum points criteria to be granted a Certificate of Sponsorship and Tier 2 visa. As appropriate, at the time an offer of appointment is made you will be asked to demonstrate that you fulfil the criteria in respect of financial maintenance and competency in English. Please do not hesitate to contact Miss Natalie Reid (e-mail firstname.lastname@example.org) for further information.
To apply online for this position visit www.abdn.ac.uk/jobs
The closing date for the receipt of applications is 8 March 2015.
Supervisory team: Professor Alistair Mathie, Ms Emma Veale, Professor Ghazwan Butrous
HIV infected patients have a > 10 fold higher incidence of pulmonary hypertension compared to the general population (e.g. Syed & Sani 2013, Heart 99 1146-1153), however the reason(s) underlying this is not clear. Recently the importance of the two-pore-domain potassium channel, TASK1, in pulmonary hypertension has been highlighted following the identification of an association between mutations in TASK1 and the disease in patients (Ma et al 2013, NEJM 369, 351-361). It is known that there is significant structural homology between the HIV-1 accessory protein Vpu and the N terminus of TASK1 and that the two proteins interact to disrupt each other’s function (Hsu et al 2004, Mol Cell 14, 259-267; Veale and Mathie unpublished observations). Using molecular biological, immunohistochemical and electrophysiological approaches, this project aims to determine the importance of this interaction in altering the functional properties of pulmonary arterial smooth muscles cells.
This position is a University of Kent 50th Anniversary Scholarship and provides tuition fees, plus a maintenance allowance, for UK and EU nationals only. Applicants should possess (or expect to possess by the summer of 2015) at least an upper second class honours degree, or equivalent, in a subject related to the project. Experience in electrophysiology is desirable but not essential.
The project will commence in September 2015.
Interested applicants should send a CV and cover letter to Professor Alistair Mathie (email@example.com) by 16 February 2015.
Professor Gianni D Angelini, British Heart Foundation (BHF) Chair of Cardiac Surgery and Director of the NIHR Cardiovascular BRU, University of Bristol and Imperial College London G.D.Angelini@bristol.ac.uk
Professor Costanza Emanueli; BHF Senior Research Fellow, Bristol coordinator in the BHF Regenerative Medicine Centres, University of Bristol Costanza.Emanueli@bristol.ac.uk
Dr. Nishith Patel, clinical lecturer in Cardiac Surgery, Imperial College London firstname.lastname@example.org
Acute kidney injury (AKI), defined as a reduction in estimated glomerular filtration rate (eGFR) of >25%, occurs in over 30% of cardiac surgery patients and is associated with a >4-fold increase in the odds of death as well as significant increases in resource use. There have been few advances in the treatment of this condition in the last 30 years and we have recently shown that clinical trials of therapeutic agents designed to ameliorate post cardiac surgery AKI have with few exceptions been unsuccessful. This is due in large part to our poor understanding of the underlying pathophysiological processes and the underpinning molecular pathways which is partly to the due absence of informative animal models allowing for basic science investigations. Notwithstanding, Patel and Angelini have recently developed a swine model of cardiopulmonary bypass (CPB)-induced AKI which has close homology to AKI in cardiac surgical patients. However, smaller animal models are necessary to integrate mechanistic research and test new therapeutic intervention.
This project will focus on microRNAs (miRs). MiRs are small, non-coding RNAs able to target short (semi)complementary nucleotide sequences within the 3′ untranslated region (UTR) of messenger RNAs (mRNAs), thus post-transcriptionally inhibiting their expression. miRs are transcribed as a primitive form (pri-miR), which is next cleaved by the Drosha ribonuclease to produce a precursor miRNA (pre-miR), which is further cleaved by Dicer to generate the mature miR. A single miR is capable of targeting multiple mRNAs; conversely a single mRNA may contain multiple miR binding sites. More than 1000 unique miRNAs have been identified within the human genome and it is suggested that one-third of expressed human genes contain miR regulatory target sites (http://www.mirbase.org/). miRs have been implicated with several cardiovascular and renal pathologies and with diabetes.
The Emanueli laboratory leads on microRNAs at international level and is part of the Leducq Transatlantic Network on Vascular microRNAs (MIRVAD). She is currently focusing her microRNA work in the cardiac surgery setting, investigating the functional and biomarker roles of extracellular microRNAs and exosomes (nanovesicle used by microRNAs as a shuttle system).
This studentship project will:
The student will be based at the Bristol Heart Institute, but he/she might be asked to spend a few months at the Imperial College London to set up the mouse model.
Candidates should preliminary send their CVs and personal statement to the supervisors. If these are considered of interest, we’ll ask to provide reference letters.
We plan to initiate this project by June 2015.